Jylamvo
Jylamvo is an oral solution that contains 2 mg/ml of methotrexate. The product was granted a European Marketing Authorisation by the European Medicines Agency (EMA) on 29 March 2017. Great Britain Marketing Authorisation granted following conversion of the EU MA on 01 January 2021. Jylamvo is authorised for use in the following indications:
In rheumatological and dermatological diseases
In oncology
Sincerely Pharmaceutical Tech
Regards,
Client Success Team (CRM),
Please fill the all required fields....!!
Sincerely Packaging Labelling